$37.87
0.30% today
Nasdaq, Sep 09, 08:46 pm CET

Collegium Pharmaceutical, Inc. Stock price

$37.75
+2.82 8.07% 1M
+8.09 27.28% 6M
+9.10 31.76% YTD
+1.05 2.86% 1Y
+20.71 121.54% 3Y
+19.34 105.05% 5Y
+22.93 154.72% 10Y
+25.46 207.16% 20Y
Nasdaq, Closing price Mon, Sep 08 2025
-0.57 1.49%

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$1.8b
Net debt
$600.8m
Cash
$222.2m
Shares outstanding
31.6m
Valuation (TTM | estimate)
P/E
41.0 | 4.5
P/S
1.7 | 1.5
EV/Sales
2.5 | 2.3
EV/FCF
8.9
P/B
5.1
Financial Health
Equity Ratio
13.8%
Return on Equity
30.2%
ROCE
11.1%
ROIC
6.5%
Debt/Equity
3.5
Financials (TTM | estimate)
Revenue
$707.0m | $771.8m
EBITDA
$337.0m | $446.4m
EBIT
$125.6m | $374.0m
Net Income
$36.3m | $265.8m
Free Cash Flow
$201.8m
Growth (TTM | estimate)
Revenue
22.6% | 22.2%
EBITDA
-2.9% | 31.7%
EBIT
-38.3% | 120.2%
Net Income
-63.7% | 284.2%
Free Cash Flow
-26.8%
Margin (TTM | estimate)
Gross
56.7%
EBITDA
47.7% | 57.8%
EBIT
17.8%
Net
5.1% | 34.4%
Free Cash Flow
28.5%
More
EPS
$0.9
FCF per Share
$6.4
Short interest
16.8%
Employees
357
Rev per Employee
$1.8m
Show more

Is Collegium Pharmaceutical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Collegium Pharmaceutical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:

Buy
82%
Hold
18%

Financial data from Collegium Pharmaceutical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
707 707
23% 23%
100%
- Direct Costs 306 306
40% 40%
43%
401 401
12% 12%
57%
- Selling and Administrative Expenses 275 275
79% 79%
39%
- Research and Development Expense - -
-
-
337 337
3% 3%
48%
- Depreciation and Amortization 211 211
47% 47%
30%
EBIT (Operating Income) EBIT 126 126
38% 38%
18%
Net Profit 36 36
64% 64%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Collegium Pharmaceutical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Collegium Pharmaceutical, Inc. Stock News

Neutral
Seeking Alpha
about 22 hours ago
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Vikram Karnani - CEO, President, Executive VP & Director Scott Dreyer - Executive VP & Chief Commercial Officer Colleen Tupper - Executive VP & CFO Conference Call Participants Robert Klingenberger Presentation Robert Klingenberger Good afterno...
Neutral
GlobeNewsWire
12 days ago
STOUGHTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 2025 Wells Fargo Healthcare Conference Thursday, September 4, 2025Boston, MA Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat Date and Time: Monday, September 8, 2025 at 2:35 p.m.
Neutral
GlobeNewsWire
15 days ago
STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain portfolio at PAINWeek 2025, taking place in Las Vegas, NV, September 2-5, 2025.
More Collegium Pharmaceutical, Inc. News

Company Profile

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.

Head office United States
CEO Vikram Karnani
Employees 357
Founded 2002
Website www.collegiumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today